Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;7(4):634-41.
doi: 10.5114/aoms.2011.24133. Epub 2011 Sep 2.

Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome

Jolanta Mieczkowska  1 , Jerzy Mosiewicz, Wojciech Barud, Wojciech Kwaśniewski
Affiliations

Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome

Jolanta Mieczkowska et al. Arch Med Sci. 2011 Aug.

Abstract

Introduction: Early atherosclerotic changes in the endothelium associated with metabolic syndrome are generated with the participation of inflammatory cells, cytokines and enzymes of the extracellular matrix. The study is aimed at a comparison between the activity of inflammatory agents, tumour necrosis factor α (TNF-α) and the enzymes of the connective tissue matrix in the blood of healthy female patients as well as those suffering from the metabolic syndrome.

Material and methods: The examination included 35 women with metabolic syndrome (MS). The control group (C) comprised 35 healthy women. Lipidogram, C-reactive protein level (CRP), fasting glucose level (FGL), matrix metalloproteinase (MMP)-8 and -9 activity, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TNF-α levels in blood were determined.

Results: As compared with the control group, the level of inflammatory factors and the activity of extracellular matrix enzymes in the metabolic syndrome were statistically higher (p < 0.05) and concerned the following parameters: TNF-α (pg/ml): MS 6.59 ±3.18, C 4.78 ±2.91; CRP (mg/dl): MS 2.18 ±2.04, C 1,26 ±1.35; TIMP-1 (ng/ml): MS 265.5 ±2.9, C 205.4 ±72.6; MMP-9 (ng/ml): MS 198.2 ±138.6, C 138.6 ±116.1. Statistically significant correlations were also found between TIMP-1 and the following factors: BMI (R = 0.400, p < 0.001), waist/hip ratio (WHR) (R = 0.278, p < 0.05), waistline (R = 0.417, p < 0.001), FGL (R = 0.290, p < 0.05), HDL cholesterol (R = -0.253, p < 0.05) and triglycerides (R = 0.269, p < 0.05).There were positive correlations of MMP-9 with FGL (R = 0.446, p < 0.001) and waistline (R = 0.260, p < 0.05); MMP-8 with FGL (R = 0.308, p < 0.05); and CRP with BMI (R = 0.370, p < 0.01), WHR (R = 0.325, p < 0.01) and waistline (R = 0.368, p < 0.01).

Conclusions: Metabolic syndrome is connected with higher activity of cytokines (TNF-α), inflammatory markers (CRP) and matrix enzymes (MMP-9, MMP-8, TIMP-1).

Keywords: atherosclerosis; cytokines; metabolic syndrome; metalloproteinase; tissue inhibitors of metalloproteinases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Spearman's correlation coefficient (R) for TIMP-1 and the following factors: obesity indices (BMI, WHR, waistline), fasting plasma glucose level, triglycerides (TG) and HDL cholesterol levels Abbreviations – see Tables I and II
See this image and copyright information in PMC

References

    1. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep. 2004;6:112–20. - PubMed
    1. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863–8. - PubMed
    1. Shanker J, Kakkar VV. Role of periodontal infection in cardiovascular disease: a current perspective. Arch Med Sci. 2009;5:125–34.
    1. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Lipid mediators that modulate the extracellular matrix structure and function in vascular cells. Curr Atheroscler Rep. 1999;1:142–9. - PubMed
    1. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:1227–34. - PMC - PubMed